Pruritus Therapeutic Market Report 2025

The pruritus therapeutic market size has grown strongly in recent years. It will grow from $14.29 billion in 2024 to $15.43 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to increasing prevalence of pruritus, advancements in research and development, growing aging population, expansion of healthcare infrastructure, increasing awareness among patients, collaborations and partnerships.

The pruritus therapeutic market size is expected to see strong growth in the next few years. It will grow to $22.02 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to continued research and innovation, emerging markets growth, rising healthcare expenditure, personalized medicine trend, regulatory support for innovation. Major trends in the forecast period include telemedicine and digital health integration, technological advancements, telehealth and digital health solutions, global regulatory landscape, biologics and immunomodulators, patient-centric approaches.

The growth of pruritus therapeutics is significantly fueled by the increasing incidences of skin disorders. Dermatologic conditions, such as acne, eczema, skin cancer, psoriasis, and vitiligo, collectively referred to as skin disorders, are on the rise. Pruritus therapeutics play a crucial role in treating various skin diseases, as pruritus is a predominant symptom in most cases. For instance, melanoma, as reported by the American Academy of Dermatology Association in April 2022, is expected to result in 7,650 deaths in 2022. Moreover, the American Cancer Society projects 97,610 new melanoma cases to be diagnosed in the United States in 2023. This increase in skin disorders underscores the driving force behind the growth of the pruritus therapeutic market.

The rising prevalence of chronic kidney disease (CKD) is anticipated to drive growth in the pruritus therapeutic market in the coming years. CKD is a long-term condition characterized by a gradual decline in kidney function and is categorized into five severity levels. Pruritus, commonly referred to as itching, is a common symptom associated with CKD. While the exact causes of pruritus in CKD are not fully understood, various factors may contribute to it. For example, in June 2023, Kidney Research UK, a charitable organization focused on research and advocacy for kidney diseases, reported that approximately 7.19 million people in the UK were living with chronic kidney disease, accounting for over 10% of the population. This number is projected to rise to 7.61 million by 2033. Consequently, the increasing incidence of chronic kidney disease is fueling the growth of the pruritus therapeutic market.

Product innovation emerges as a prominent trend in the pruritus therapeutic market, with major companies focusing on the development of innovative medications and treatments for pruritus and related conditions. An example is Maruho Co., Ltd., a Japan-based pharmaceutical company, which introduced the anti-IL-31 receptor, a humanized monoclonal antibody named Mitchga Subcutaneous Injection. Launched in August 2022, it serves as a treatment for itching associated with atopic dermatitis, inhibiting IL-31 signaling and addressing pruritus and skin inflammation.

Major companies in the pruritus therapeutic market are adopting a strategic partnership approach to address moderate-to-severe atopic dermatitis. This collaborative strategy involves leveraging each other's strengths and resources for mutual benefits. Amgen Inc., a US-based biopharmaceutical company, partnered with Kyowa Kirin to investigate rocatinlimab, a potential anti-OX40 monoclonal antibody for moderate to severe atopic dermatitis. The Phase 3 trial, known as ROCKET, is a global initiative aimed at studying the safety and effectiveness of rocatinlimab. This strategic partnership underscores the collaborative efforts in advancing therapeutic solutions.

In March 2023, Ipsen, a France-based biopharmaceutical company, acquired Albireo Pharma, Inc., a US-based biopharmaceutical company. This strategic acquisition adds promising therapies for uncommon cholestatic liver disorders, novel pipeline prospects, and technical and financial strength to Ipsen’s portfolio. Albireo Pharma, Inc. specializes in developing and commercializing novel bile acid modulators for the treatment of orphan pediatric liver diseases, gastrointestinal disorders, and pruritus-related conditions in drug development.

Major companies operating in the pruritus therapeutic market include Astellas Pharma Inc., Bristol-Myers Squibb Company, Cipla Inc., Eli Lilly and Company, Galderma Laboratories LP, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Abbott Laboratories, Almirall SA, Eisai Co. Ltd., Glenmark Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Chemicals Ltd., Cara Therapeutics Inc., EPI Health LLC, AbbVie Inc., Albireo Pharma Inc., Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Huapont Life Sciences Co. Ltd., LEO Pharma AS, MC2 Therapeutics Ltd., Novan Inc., Trevi Therapeutics Inc., UCB SA, Viatris Inc., Teva Pharmaceutical Industries Ltd.

North America was the largest region in the pruritus therapeutic market in 2024. The regions covered in the pruritus therapeutic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pruritus therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pruritus therapeutic refers to the treatment of pruritus, an uncomfortable sensation that prompts a person to scratch. Pruritus can be caused by various factors, including contact with allergens, dry skin, pregnancy, and reactions to medications.

The main types of pruritus therapeutic treatments include corticosteroids, antihistamines, local anesthetics, counterirritants, immunosuppressants, calcineurin inhibitors, and others. Corticosteroids are a type of anti-inflammatory medication that closely resembles the hormone cortisol naturally produced by the adrenal glands. Pruritus can manifest in different diseases such as atopic dermatitis or eczema, allergic contact dermatitis, urticaria, cutaneous T-cell lymphoma, and others. Treatment methods include external use through application, oral administration, and injection. These therapies are commonly employed by hospitals, clinics, and other medical facilities.

The pruritus therapeutic market research report is one of a series of new reports that provides pruritus therapeutic market statistics, including pruritus therapeutic industry global market size, regional shares, competitors with a pruritus therapeutic market share, detailed pruritus therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the pruritus therapeutic industry. This pruritus therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pruritus therapeutic market includes revenues earned by entities by treating pruritus conditions with medicines such as aloe vera, menthol and petroleum jelly. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.